林鄭:政府與兩疫苗製造商訂協議分別供應750萬劑 首批最快1月到港
行政長官林鄭月娥出席記者會時表示,政府在疫苗採購方面有突破性發展,一方面香港已參加世衛的疫苗獲取機制,已繳付按金獲取總人口三成半的疫苗劑量,另外亦有洽談並尋求與個別疫苗製造商簽署預先採購協議,為全港人口免費接種疫苗,採購目標是起碼買到兩款來自不同製造商及不同疫苗技術平台的疫苗,即是採購量是全港人口的兩倍,如疫苗需要接種兩劑,即是最高採購劑量達到3,000萬劑。
她指出現時已與兩家疫苗製商商達成協議,當中科興控股生物技術(SYNOVEX)會供應750萬劑,首批100萬劑可望最快明年1月來港,另一製造商是復星醫藥(02196.HK)、德國BioNTech及輝瑞藥廠,將供應750萬劑,首批最快明年首季來港。而另外第三間在談、即將達成協議的是阿斯利康,可供應750萬劑,最快到明年下半年到港。她指出會安排優先群組進行接種,包括是醫護及長者等,期望明年內為大部分香港市民提供免費接種疫苗,並盡快恢復出行、商業活動等。
林鄭指出,香港自11月下旬開始有新一波疫情,至今情況令人非常擔憂,而且今次是因本地個案不斷增加所帶動,而本地個案中未有源頭的個案比例持續上升,相關比例亦於最近一周達到逾三成,每宗源頭不明本地個案都反映社區有隱形傳播鏈,帶來更大風險,故社交距離措施要更嚴格,發揮切斷傳播鏈的作用。她強調對疫苗採購工作從來無掉以輕心,並有嚴謹認真跟進採購工作,不過當中涉科學評估、採購亦涉商業協議,難公開透明每個階段與大家分享採購工作進程。(el/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.